AGP Executive Report
Last update: 4 hours agoBiopharma Dealmaking: Fosun Pharma is doubling down on Alzheimer’s by signing an exclusive global option with AriBio for AR1001, with Fosun set to pay up to USD240M more for rights in major markets like the US and Europe, after already securing China/HK/Macao and parts of ASEAN. Oncology Target Rush: A once “untouchable” cancer antigen, B7-H3, is suddenly crowded with new programs, including a fresh NK-cell engager entering Phase 1—showing how fast oncology target strategies are shifting. Ophthalmology Confidence Check: EyePoint says an independent DSMC gave a third straight positive recommendation for its Phase 3 wet AMD trials of DURAVYU, with topline data still aimed for mid-2026. Macao Health Access: The MOP700 medical e-voucher scheme stays at the same level and will expand use to Guangdong clinics starting next month, while Macau also confirmed its first imported malaria case this year. Local Life & Health Culture: More than 20 museums will kick off the Macao International Museum Day Carnival 2026 at Lotus Square on Sunday.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
